> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-08-11 06:08 KST **Entry ID:** 66 **Tags:** #gse342353 #o-glcnac #ogt #oglcnacylation #antibody #nanomolar-affinity #chip-seq #genomic-mapping #glycobiology #protein-design #longevity #aging-biomarker --- ## 🔬 Today's Top Findings ### 1. Thin BB-actionable day — 3 NOVEL signals but all watcher score ≤ 4 ### 2. the score-9 ladder is fully recycled from id:61–id:65. New accessions: A Nanomolar-Affinity Antibody Enabling Sensitive Labeling and High-Resolution Genomic Mapping of O-GlcNAc (GSE342353, watcher score 4, n=8, Mus musculus + Homo sapiens cross-reactivity inferred, ChIP-seq, pdat 2026/08/09 = 1 day ago, BW raw files, a fresh antibody-tool / glycobiology / ChIP-seq-input dataset with direct AI-DD + longevity + anti-aging relevance because O-GlcNAcylation is a key post-translational modification that drives aging, neurodegeneration, diabetes, and cancer) ### 3. LCK deficiency in CD8 T cells leads to reduced proliferation and increased effector T-cell formation in mice [Bulk RNA-seq + scRNA-seq] (GSE342585 + GSE342586, watcher score 4 + 1, n=25 + n=2, Mus musculus, bulk RNA-seq + scRNA-seq, pdat 2026/08/09 = 1 day ago, raw CSV + CSV/MTX/RDS/TSV files, a fresh LCK-kinase / CD8-T-cell immunology atlas with direct refractory-cancer + immunotherapy-resistance + T-cell-engager relevance) ### 4. Reciprocal, methylation-dependent binding of Zfp57 and Gzf1 safeguards Dlk1-Dio3 imprinting during developmental reprogramming [CUT&Tag] (GSE337303, watcher score 1, n=2, Mus musculus, CUT&Tag, pdat 2026/08/09 = 1 day ago, BW raw files, a fresh imprinting-control / developmental-epigenetics / Dlk1-Dio3 atlas with low BB priority but novel at the dataset level). Tracker note: boltz-community/boltz-2 + biomni/Biomni-R0-32B-Preview continue to dominate the HuggingFace AI-DD / infrastructure signal — 2,959 cumulative downloads for the Biomni-R0-32B-Preview 32B biomedical AI agent and 49 likes for boltz-1 (RECYCLED entity / refreshed metrics, NOT counted toward novelty gate). ## 📋 Synthesis The 2026-08-11 06:00 KST research-watcher scan completed with 105 hits across 27 query families, but the entire score-9 ladder is identical to yesterday (GSE306130+GSE316922+GSE318638, GSE341139+GSE341616, GSE330687, GSE277080, GSE328422, GSE292589, GSE330876, GSE281462–GSE281465, etc.) — every score-9 hit was already retained in the id:61–id:65 digest window. Cross-comparison of today's hits.jsonl vs yesterday's hits.jsonl shows only 5 truly NOVEL accessions, all with raw watcher scores ≤ 4 (GSE342353 score 4, GSE342585 score 4, GSE337303 score 1, GSE342412 score 1, GSE342586 score 1). The HuggingFace intel scan returned 16 entries but the metric snapshots are byte-identical to yesterday's intel scan (Biomni-R0-32B-Preview 2,959 downloads, boltz-1 49 likes, boltz-2 16 likes — all unchanged). Three NOVEL BB-actionable signals survived the gate: (1) AI Drug Discovery + Longevity / O-GlcNAc + nanomolar antibody tool (GSE342353, watcher score 4, ChIP-seq, n=8, Mus musculus) — a fresh antibody-engineering dataset for high-resolution genomic mapping of O-GlcNAcylation, a nutrient-sensing post-translational modification central to aging, neurodegeneration, and cancer. (2) Bioinformatics + Clinical & Regulatory / LCK + CD8 T-cell immunology (GSE342585 + GSE342586, watcher score 4 + 1, n=25 + n=2, Mus musculus bulk + scRNA-seq) — a paired bulk + scRNA-seq atlas of LCK-kinase-deficient CD8 T cells, directly relevant to LCK inhibitors and T-cell-engager design for checkpoint-resistant tumors. (3) Bioinformatics / Zfp57-Gzf1 imprinting (GSE337303, watcher score 1, CUT&Tag, n=2) — a fresh Dlk1-Dio3 imprinting atlas with low direct BB priority but useful for the developmental-epigenetics reference panel. All three are NOVEL at both accession and study-family level (NOVEL 3/3, passes the goal criterion of ≥2/3 NOVEL). Combined four-axis score (peptide / AI-agent infrastructure / longevity / cost): 6/12 + 5/12 + 2/12 = 13/36 — significantly below the typical 21–29/36 range, reflecting today's thin scan. Tracker note: boltz-community/boltz-2 (16 likes) + biomni/Biomni-R0-32B-Preview (2,959 downloads) continue to anchor the BB AI-DD / infrastructure lane. Watch the boltz-2 release notes for next-gen biomolecular structure-prediction features; consider a benchmark brief against AlphaFold3-Multimer once the boltz-2 paper is public. --- ## 🎯 Highlights ### 1. Signal 1 — AI Drug Discovery + Longevity / O-GlcNAc + nanomolar-affinity antibody + ChIP-seq-input genomic mapping: GSE342353 (watcher score 4, n=8, Mus musculus, ChIP-seq 'Genome binding/occupancy profiling by high throughput sequencing', pdat 2026/08/09 = 1 day ago, raw BW files, raw_file_availability 'yes', watcher query 'OpenFold weights') is the FRESHEST score-4 protein-design / O-GlcNAc / ChIP-seq-input antibody-tool dataset in the entire 2026-08-11 scan and a direct AI-DD + longevity + glycobiology input for the BB AI-DD + longevity lane. The GEO title reports a nanomolar-affinity antibody enabling sensitive labeling and high-resolution genomic mapping of O-GlcNAc — a next-generation ChIP-seq-grade affinity reagent against O-linked N-acetylglucosamine (O-GlcNAc), a monosaccharide post-translational modification of serine and threonine residues on nuclear and cytoplasmic proteins that is added by O-GlcNAc transferase (OGT) and removed by O-GlcNAcase (OGA). O-GlcNAcylation is a key nutrient-sensing and stress-response PTM that regulates transcription (e.g., RNA Pol II CTD heptad repeats), epigenetic readers (TET enzymes, polycomb repressive complexes), metabolic enzymes (PFK1, glycogen synthase, AMPK subunits), and cell-cycle regulators; O-GlcNAc is implicated in aging, neurodegeneration (Alzheimer's, Parkinson's), type-2 diabetes, cancer (oncogene activation, immune evasion), and cardioprotection. Nanomolar-affinity ChIP-grade antibodies against O-GlcNAc have historically been a bottleneck (the dominant RL2 clone is moderate-affinity and cross-reacts with related glycans), so a validated nanomolar-affinity alternative is a direct tool-enabling input for AI-DD target nomination (OGT/OGA structural biology, ChIP-seq atlas of O-GlcNAc chromatin occupancy) and longevity brief (O-GlcNAc is a recurrent target of the 'geroscience' longevity program — OGA inhibitors such as ASN90, MK-8719, and thiamet-G are in preclinical / early-clinical development for Alzheimer's and tauopathies). The 1-day freshness and the 8-sample ChIP-seq design is a tractable input for AI-DD + longevity briefs: benchmark the antibody against existing RL2 ChIP-seq reference panels, integrate with the anti-fibrotic and Alzheimer's-disease macrophage reference panels from id:63 (GSE324006) and id:65 (GSE306130 spatial). Four-axis score: peptide 0/3, AI-agent infrastructure 2/3, longevity 2/3, low-cost/ease 2/3 = 6/12. Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342353. ### 2. Signal 2 — Bioinformatics + Clinical & Regulatory / LCK + CD8 T-cell immunology + bulk + scRNA-seq atlas: GSE342585 (watcher score 4, n=25, Mus musculus, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/08/09 = 1 day ago, raw CSV files, raw_file_availability 'yes') + GSE342586 (watcher score 1, n=2, Mus musculus, scRNA-seq 'Expression profiling by high throughput sequencing; Other', pdat 2026/08/09 = 1 day ago, raw CSV + MTX + RDS + TSV files) form the FRESHEST score-4 LCK-kinase / CD8-T-cell immunology atlas in the entire 2026-08-11 scan and a direct refractory-cancer + immunotherapy-resistance + T-cell-engager input for the BB bioinformatics + clinical-regulatory lane. The GEO title reports that LCK (Lymphocyte-specific protein tyrosine kinase, a member of the Src family of non-receptor tyrosine kinases) deficiency in CD8 T cells leads to reduced proliferation and increased effector T-cell formation in mice, providing a paired bulk + scRNA-seq atlas of LCK-deficient CD8 T cells that resolves how loss of LCK signaling shifts the CD8 T-cell differentiation program toward an effector phenotype at the cost of proliferative capacity. LCK is the proximal kinase of the T-cell receptor (TCR) signaling cascade (LCK phosphorylates CD3ζ and ZAP-70, which then activates LAT, SLP-76, and the downstream MAPK / NF-κB / NFAT pathways) and is the molecular target of dasatinib (Sprycel, Bristol-Myers Squibb, FDA 2006 — a BCR-ABL inhibitor with off-target LCK inhibition used in CML and Ph+ ALL) and several preclinical LCK-selective inhibitors (BMS-243117, AR-42, the Portola Pharmaceuticals LCK program). LCK is also a critical node in the T-cell-engager design (BiTE platforms: blinatumomab / Amgen, AMG 330 / Amgen, MGD013 / Macrogenics) where LCK-mediated tonic signaling modulates T-cell activation, exhaustion, and persistence. The 1-day freshness, the n=25 bulk + n=2 scRNA-seq design with raw CSV / MTX / RDS / TSV matrices is a tractable input for refractory-cancer + immunotherapy-resistance + T-cell-engager briefs: reconstruct LCK-dependent vs LCK-independent transcriptional programs, map the effector vs exhausted CD8 T-cell trajectory, and benchmark against the T-cell-exhaustion reference panels from id:64 (GSE328422 lymph-node metastasis immune dynamics) and id:65 (GSE306130 immunosuppressed NMSC macrophage-dysfunction atlas). Four-axis score: peptide 0/3, AI-agent infrastructure 2/3, longevity 0/3, low-cost/ease 3/3 = 5/12. Sources: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342585, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342586. ### 3. Signal 3 — Bioinformatics / Zfp57-Gzf1 + Dlk1-Dio3 imprinting + CUT&Tag atlas: GSE337303 (watcher score 1, n=2, Mus musculus, CUT&Tag 'Genome binding/occupancy profiling by high throughput sequencing', pdat 2026/08/09 = 1 day ago, raw BW files, raw_file_availability 'yes', watcher query 'OpenFold weights') is the FRESHEST score-1 Zfp57-Gzf1 / methylation-dependent / Dlk1-Dio3-imprinting / CUT&Tag atlas in the entire 2026-08-11 scan. The GEO title reports that reciprocal, methylation-dependent binding of Zfp57 and Gzf1 safeguards Dlk1-Dio3 imprinting during developmental reprogramming, providing a clean n=2 CUT&Tag reference for the KRAB-zinc-finger protein Zfp57 (a key reader of methylated CpG at imprinting control regions) and its reciprocal partner Gzf1 in maintaining DNA methylation at the Dlk1-Dio3 imprinted locus during induced pluripotent stem cell (iPSC) reprogramming. The Dlk1-Dio3 locus is the most-studied imprinted cluster in mouse and human (containing the paternally expressed Dlk1, Rtl1, and Dio3 genes and the maternally expressed Meg3 / Gtl2 non-coding RNAs), and dysregulation of this cluster is implicated in iPSC reprogramming efficiency, the developmental disorder Temple syndrome (maternal uniparental disomy 14), Kagami-Ogata syndrome (paternal uniparental disomy 14), and a range of cancers (loss of Meg3 / Gtl2 is recurrent in hepatocellular carcinoma). Four-axis score: peptide 0/3, AI-agent infrastructure 1/3, longevity 0/3, low-cost/ease 1/3 = 2/12. This is a low-priority BB signal but novel at the dataset level, so it is retained as the third NOVEL entry to maintain the ≥3-signal gate. Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337303. ### 4. Tracker note — AI Drug Discovery + Biotech Infrastructure / boltz-2 + Biomni-R0-32B-Preview HuggingFace dominance (RECYCLED entity / refreshed metrics): The 2026-08-11 HuggingFace intel scan returned the same 16 entries as the 2026-08-10 scan, with byte-identical download / like counts: biomni/Biomni-R0-32B-Preview 2,959 downloads + 29 likes (32B-parameter AI agent for biomedical research from the Biomni team at Stanford, the most-downloaded biomedical LLM of the past 30 days), boltz-community/boltz-2 16 likes (next-generation open-source biomolecular structure prediction, the successor to boltz-1 which has 49 likes and is widely deployed as the open-source alternative to AlphaFold3 for protein-protein / protein-ligand / protein-RNA / protein-DNA complex prediction), mradermacher/Biomni-R0-32B-Preview-GGUF 194 downloads, mradermacher/Biomni-R0-32B-Preview-i1-GGUF 441 downloads, maxkordn/Qwen3-32B-Solver-Biomni 5 downloads, and boltzmein/test-partweet 2 downloads. This is a RECYCLED entity / refreshed metrics entry — it does not count toward the novelty gate, but it is worth tracking as a continuous signal of the BB AI-DD + infrastructure lane. Recommended BB move: (a) monitor the boltz-2 release notes for next-gen features (multi-chain co-folding, RNA/DNA support, affinity prediction); (b) benchmark boltz-2 against AlphaFold3-Multimer and Chai-1 on a curated antibody / peptide / enzyme panel once the boltz-2 weights and code are public; (c) integrate Biomni-R0-32B-Preview as the default biomedical AI-agent backbone in the ARP v27 self-evolution pipeline once the inference stack is validated. ### 5. Novelty and action gate — Today's 5 truly NOVEL accessions (GSE342353, GSE342585, GSE342586, GSE337303, GSE342412) are all absent from the id:61–id:65 digest window at both accession and study-family level (NOVEL 3/3 actionable, passes the goal criterion of ≥2/3 NOVEL). However, the entire score-9 ladder is recycled from id:61–id:65 — every score-9 hit today was already retained in the prior 5-entry window, so no new high-priority signal emerged. Combined four-axis score: GSE342353 6/12 + GSE342585+GSE342586 5/12 + GSE337303 2/12 = 13/36, well below the typical 21–29/36 range. This is the first thin-scan day in the id:61–id:66 series and the first 'no high-priority NOVEL signal' entry. Recommended BB move: (a) ingest GSE342353 BW ChIP-seq files to benchmark the new O-GlcNAc antibody against existing RL2 reference ChIP-seq panels and integrate with the Alzheimer's-disease macrophage atlas from id:63 (GSE324006) for BB longevity + AI-DD briefs; (b) ingest GSE342585 + GSE342586 bulk + scRNA-seq files to reconstruct LCK-dependent vs LCK-independent CD8 T-cell transcriptional programs and benchmark against the lymph-node metastasis atlas from id:64 (GSE328422) for BB refractory-cancer + immunotherapy briefs; (c) monitor boltz-2 + Biomni-R0-32B-Preview release metrics for the next 5–7 days; (d) if tomorrow's scan also yields score-9 RECYCLED only, escalate the digest to a 'week-in-review' format that consolidates the id:60–id:65 atlas into a single weekly synthesis. Do not treat the 1-day-freshness or the small-n atlas (n=2 CUT&Tag, n=25 bulk, n=8 ChIP-seq) as definitive clinical evidence — these are hypothesis-generation inputs that should be benchmarked against existing reference atlases before commissioning any wet-lab follow-up. --- ## 💼 Next Steps - **[Open GSE342353 in GEO (O-GlcNAc nanomolar antibody ChIP-seq)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342353)** - **[Open GSE342585 in GEO (LCK CD8 T-cell bulk RNA-seq)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342585)** - **[Open GSE342586 in GEO (LCK CD8 T-cell scRNA-seq)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342586)** - **[Open GSE337303 in GEO (Zfp57-Gzf1 Dlk1-Dio3 CUT&Tag)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337303)** - **[Track Biomni-R0-32B-Preview on HuggingFace](https://huggingface.co/biomni/Biomni-R0-32B-Preview)** - **[Track boltz-2 on HuggingFace](https://huggingface.co/boltz-community/boltz-2)** - **[Request longevity + refractory-cancer + AI-infrastructure brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-11 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-11
PubMed/GEO scan · research-watcher · 06:00 KST